VanEck Pharmaceutical ETF

PPH

時価総額 $10.7億

Simplify Health Care ETF has a higher expense ratio and a lower dividend yield than VanEck Pharmaceutical ETF. VanEck Pharmaceutical ETF maintains a more concentrated portfolio focused exclusively on global pharmaceutical giants.

Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on December 20, 2011.

The VanEck Pharmaceutical ETF offers a lower expense ratio of 0.36% compared to 0.58% for the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF has delivered a higher 1-year total return of 41% relative to 31% for the VanEck fund.

The Invesco S&P 500 Equal Weight Health Care ETF provides broader exposure with 60 holdings compared to 26 for the VanEck Pharmaceutical ETF. The VanEck Pharmaceutical ETF currently offers a significantly higher dividend yield and a lower expense ratio than its counterpart.

Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.

FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.

The iShares U.S. Healthcare ETF (NYSEMKT:IYH) provides broad exposure across the healthcare sector, whereas the VanEck Pharmaceutical ETF (NYSEMKT:PPH) concentrates specifically on pharmaceutical stocks. PPH offers a slightly lower expense ratio and a higher dividend yield than IYH.

VanEck Pharmaceutical ETF features a lower expense ratio of 0.36% compared to 0.58% for Invesco Biotechnology & Genome ETF. Invesco Biotechnology & Genome ETF delivered a higher 1-year total return of 47.3% but experienced a significantly deeper maximum drawdown of 34.7%.

Launched on December 20, 2011, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.